Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.46 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238314 | 0.94 | UBE2T (0.48) | MAPTSMN1; SMN2HPGDSKCNJ1HRH3 | |
| SCHEMBL1896186 | 0.86 | KCNH2 (0.53) | HPGDSHRH3KCNH2HDAC2HDAC3 | |
| SCHEMBL23929985 | 0.85 | UBE2T (0.61) | MAPTSMN1; SMN2HPGDSKCNJ1HRH3 | |
| SCHEMBL30175332 | 0.85 | UBE2T (0.61) | MAPTSMN1; SMN2HPGDSKCNJ1HRH3 | |
| SCHEMBL25022813 | 0.85 | UBE2T (0.57) | MAPTSMN1; SMN2KCNJ1HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31552815 | 0.84 | KCNH2 (0.52) | HPGDSHRH3KCNH2HDAC2HDAC3 | |
| SCHEMBL7550033 | 0.84 | KCNH2 (0.52) | HPGDSHRH3KCNH2HDAC2HDAC3 | |
| SCHEMBL29524173 | 0.84 | PARP1 (0.53) | HPGDSHRH3KCNH2HDAC2HDAC3 | |
| SCHEMBL7547417 | 0.84 | KCNH2 (0.52) | HPGDSHRH3KCNH2HDAC2HDAC3 | |
| SCHEMBL2706925 | 0.84 | PARP1 (0.53) | HPGDSHRH3KCNH2HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9078896-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140135341-A1 | Pyridine And Pyrimidine Derivatives As Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-05-15 | — | — | US | disclosed |
| US-8664223-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V (BE) | 2014-03-04 | — | — | US | disclosed |
| US-20130143898-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-06 | — | — | US | disclosed |
| US-8114876-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-8101616-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BG) | 2012-01-24 | — | — | US | disclosed |
| US-7834011-B2 | Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-16 | — | — | US | disclosed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1858868-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1856077-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094843-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094843-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094840-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094840-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | SLC6A7, SLC6A5, SLC1A2 | MAPT 441/4885SMN1; SMN2 3532/4885HPGDS 2575/4885 |
| US-20140135341-A1 | Pyridine And Pyrimidine Derivatives As Inhibitors Of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | MAPT 2987/4885SMN1; SMN2 4045/4885HPGDS 893/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | MAPT 3831/4885SMN1; SMN2 4607/4885HPGDS 2344/4885 |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | MAPT 3053/4885SMN1; SMN2 1719/4885HPGDS 959/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | MAPT 3053/4885SMN1; SMN2 1719/4885HPGDS 959/4885 |
| US-20130143898-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | MAPT 2987/4885SMN1; SMN2 4045/4885HPGDS 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.